-- サテン・クレジットケア・ネットワーク(NSE:SATIN、BOM:539404)は、7年満期の劣後ティア2資本として20億インドルピーを調達したと、木曜日にインド証券取引所に提出した書類で明らかにした。 この長期の資本調達は、同社の自己資本比率の向上に貢献し、中核事業および新興事業プラットフォームの拡大に向けた緩衝材となる、と同社は声明で述べた。 同社は調達資金を、収益を生み出す融資や水・衛生・保健関連の融資など、影響力の大きい融資分野の拡大、および子会社の成長支援に充てる予定だ。 同社の株価は直近の取引で約4%上昇した。
Related Articles
Jagsonpal Pharmaceuticals Sets Dates for INR400 Million Buyback
Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM, BOM:507789) has fixed May 8 as the opening date and May 14 as the closing date for its share buyback plan worth 400 million, according to a Wednesday filing on Indian bourses.Shares of the company rose nearly 2% in Thursday's trade.The company will buy back up to 1.6 million equity shares at 250 rupees per share through the tender offer route, the filing said.
Research Alert: CFRA Maintains Strong Buy Opinion On Shares Of Arch Capital Group Ltd.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month targe price to $115 from ($118), valuing ACGL shares at 10.9x our '27 operating EPS estimate of $10.55 (lowered today by $0.40) and at 11.6x our '26 EPS estimate of $9.93 (cut by $0.12), versus the shares' three-year average forward multiple and the peer average of 12x. ACGL posted Q1 operating EPS of $2.50 vs. $1.54 the prior year, beating the $2.46 consensus but missing our $2.62 estimate. However, operating revenues declined 1.3% Y/Y, significantly below our 8%-15% growth forecast, reflecting 4.8% lower earned premiums partly offset by 8% higher investment income. We view ACGL as a top-tier underwriter with superior underwriting capabilities, maintaining strong profitability metrics despite competitive headwinds. We now see revenue growth of 3%-5% in 2026 and 2027. Underlying underwriting results remained superior to industry averages, with the combined ratio at 82.3% vs. 81.0% the prior year, about 5-10 points better than industry, which will support EPS.